Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 16.07
NVO's Cash to Debt is ranked higher than
76% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: 16.07 vs. NVO: 16.07 )
NVO' s 10-Year Cash to Debt Range
Min: 0.29   Max: No Debt
Current: 16.07

Equity to Asset 0.58
NVO's Equity to Asset is ranked higher than
69% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. NVO: 0.58 )
NVO' s 10-Year Equity to Asset Range
Min: 0.51   Max: 0.73
Current: 0.58

0.51
0.73
Interest Coverage 572.60
NVO's Interest Coverage is ranked higher than
60% of the 439 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NVO: 572.60 )
NVO' s 10-Year Interest Coverage Range
Min: 4.79   Max: 572.6
Current: 572.6

4.79
572.6
F-Score: 7
Z-Score: 21.39
M-Score: -2.25
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 38.15
NVO's Operating margin (%) is ranked higher than
97% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. NVO: 38.15 )
NVO' s 10-Year Operating margin (%) Range
Min: 10.5   Max: 37.77
Current: 38.15

10.5
37.77
Net-margin (%) 30.79
NVO's Net-margin (%) is ranked higher than
96% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: -69.57 vs. NVO: 30.79 )
NVO' s 10-Year Net-margin (%) Range
Min: 10.59   Max: 30.13
Current: 30.79

10.59
30.13
ROE (%) 69.20
NVO's ROE (%) is ranked higher than
99% of the 877 Companies
in the Global Biotechnology industry.

( Industry Median: -28.59 vs. NVO: 69.20 )
NVO' s 10-Year ROE (%) Range
Min: 11.34   Max: 60.54
Current: 69.2

11.34
60.54
ROA (%) 39.31
NVO's ROA (%) is ranked higher than
98% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -21.69 vs. NVO: 39.31 )
NVO' s 10-Year ROA (%) Range
Min: 7.57   Max: 37.03
Current: 39.31

7.57
37.03
ROC (Joel Greenblatt) (%) 129.33
NVO's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: -217.20 vs. NVO: 129.33 )
NVO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 6.89   Max: 126.76
Current: 129.33

6.89
126.76
Revenue Growth (%) 14.30
NVO's Revenue Growth (%) is ranked higher than
86% of the 646 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. NVO: 14.30 )
NVO' s 10-Year Revenue Growth (%) Range
Min: 0.3   Max: 23
Current: 14.3

0.3
23
EBITDA Growth (%) 19.00
NVO's EBITDA Growth (%) is ranked higher than
91% of the 621 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. NVO: 19.00 )
NVO' s 10-Year EBITDA Growth (%) Range
Min: 8.4   Max: 25.7
Current: 19

8.4
25.7
EPS Growth (%) 23.90
NVO's EPS Growth (%) is ranked higher than
91% of the 649 Companies
in the Global Biotechnology industry.

( Industry Median: -10.10 vs. NVO: 23.90 )
NVO' s 10-Year EPS Growth (%) Range
Min: 10.3   Max: 29.7
Current: 23.9

10.3
29.7
» NVO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

NVO Guru Trades in Q3 2013

Steven Cohen 6,102 sh (+41.64%)
Ruane Cunniff 39,186 sh (+13.12%)
Jim Simons 3,136,200 sh (+12.22%)
Ken Fisher 2,702,841 sh (+0.43%)
Murray Stahl 1,548 sh (unchged)
Mario Gabelli 1,704 sh (-0.58%)
Tom Gayner 221,700 sh (-1.51%)
» More
Q4 2013

NVO Guru Trades in Q4 2013

Murray Stahl 7,740 sh (+400%)
Ruane Cunniff 62,194 sh (+58.71%)
Jim Simons 3,263,700 sh (+4.07%)
Ken Fisher 2,710,787 sh (+0.29%)
Mario Gabelli 1,704 sh (unchged)
Tom Gayner 221,200 sh (-0.23%)
Steven Cohen 3,141 sh (-48.53%)
» More
Q1 2014

NVO Guru Trades in Q1 2014

Ken Fisher 13,631,979 sh (+0.58%)
Jim Simons 16,079,800 sh (-1.46%)
Tom Gayner 1,075,000 sh (-2.8%)
Mario Gabelli 7,665 sh (-10.04%)
Ruane Cunniff 242,630 sh (-21.98%)
Steven Cohen 9,962 sh (-36.57%)
Murray Stahl 7,740 sh (-80%)
» More
Q2 2014

NVO Guru Trades in Q2 2014

Jim Simons 16,953,000 sh (+5.43%)
Ken Fisher 13,741,529 sh (+0.8%)
Murray Stahl 7,740 sh (unchged)
Tom Gayner 1,075,000 sh (unchged)
Mario Gabelli 7,620 sh (-0.59%)
Ruane Cunniff 160,492 sh (-33.85%)
» More
» Details

Insider Trades

Latest Guru Trades with NVO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ruane Cunniff 2014-06-30 Reduce -33.85%0.02%$42.28 - $46.52 $ 47.828%160492
Ruane Cunniff 2014-03-31 Reduce -21.98%0.01%$36.722 - $48.23 $ 47.8213%242630
Ruane Cunniff 2013-12-31 Add 58.71%0.02%$32.72 - $36.886 $ 47.8237%62194
Ruane Cunniff 2013-06-30 New Buy0.04%$30.11 - $35.33 $ 47.8244%34640
Mario Gabelli 2013-03-31 Reduce -60.32%$32.24 - $38.86 $ 47.8237%1734
John Hussman 2012-09-30 Sold Out 0.01%$28.83 - $32.15 $ 47.8256%0
John Hussman 2012-03-31 Reduce -40%$23.09 - $28.94 $ 47.8293%3000
Mario Gabelli 2011-12-31 Add 66.87%$18.92 - $23.05 $ 47.82122%5590
John Hussman 2011-09-30 New Buy0.01%$19.46 - $25.45 $ 47.82115%5000
John Keeley 2011-06-30 Sold Out 0.01%$23.4 - $26.29 $ 47.8292%0
Mario Gabelli 2011-06-30 Reduce -21.18%$23.4 - $26.29 $ 47.8292%3350
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Novo Nordisk A/S

Weekly 52-Week Highs Highlight: ACT, NVO, NXPI, WYNN
According to GuruFocus list of 52-week highs; Actavis PLC, Novo Nordisk A/S, NXP Semiconductor NV and Wynn Resorts Ltd. have all reached their 52 week highs. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 29.20
NVO's P/E(ttm) is ranked higher than
93% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NVO: 29.20 )
NVO' s 10-Year P/E(ttm) Range
Min: 12.11   Max: 32.39
Current: 29.2

12.11
32.39
P/B 21.40
NVO's P/B is ranked higher than
60% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 5.80 vs. NVO: 21.40 )
NVO' s 10-Year P/B Range
Min: 1.7   Max: 21.31
Current: 21.4

1.7
21.31
P/S 8.90
NVO's P/S is ranked higher than
81% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 20.06 vs. NVO: 8.90 )
NVO' s 10-Year P/S Range
Min: 2.81   Max: 8.97
Current: 8.9

2.81
8.97
PFCF 37.40
NVO's PFCF is ranked higher than
95% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NVO: 37.40 )
NVO' s 10-Year PFCF Range
Min: 12.1   Max: 47.01
Current: 37.4

12.1
47.01
EV-to-EBIT 24.13
NVO's EV-to-EBIT is ranked higher than
93% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NVO: 24.13 )
NVO' s 10-Year EV-to-EBIT Range
Min: 9.1   Max: 25.3
Current: 24.13

9.1
25.3
PEG 1.31
NVO's PEG is ranked higher than
99% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NVO: 1.31 )
NVO' s 10-Year PEG Range
Min: 0.14   Max: 1.79
Current: 1.31

0.14
1.79
Shiller P/E 42.50
NVO's Shiller P/E is ranked higher than
96% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NVO: 42.50 )
NVO' s 10-Year Shiller P/E Range
Min: 18.94   Max: 43.06
Current: 42.5

18.94
43.06
Current Ratio 1.44
NVO's Current Ratio is ranked higher than
57% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. NVO: 1.44 )
NVO' s 10-Year Current Ratio Range
Min: 1.31   Max: 2.88
Current: 1.44

1.31
2.88
Quick Ratio 0.99
NVO's Quick Ratio is ranked higher than
55% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 3.81 vs. NVO: 0.99 )
NVO' s 10-Year Quick Ratio Range
Min: 0.92   Max: 2.34
Current: 0.99

0.92
2.34

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.30
NVO's Dividend Yield is ranked higher than
75% of the 176 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. NVO: 1.30 )
NVO' s 10-Year Dividend Yield Range
Min: 1.02   Max: 2.47
Current: 1.3

1.02
2.47
Dividend Payout 0.34
NVO's Dividend Payout is ranked higher than
95% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NVO: 0.34 )
NVO' s 10-Year Dividend Payout Range
Min: 0.51   Max: 1.61
Current: 0.34

0.51
1.61
Dividend growth (3y) 33.90
NVO's Dividend growth (3y) is ranked higher than
95% of the 80 Companies
in the Global Biotechnology industry.

( Industry Median: 11.10 vs. NVO: 33.90 )
NVO' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 37.5
Current: 33.9

0
37.5
Yield on cost (5-Year) 3.84
NVO's Yield on cost (5-Year) is ranked higher than
95% of the 182 Companies
in the Global Biotechnology industry.

( Industry Median: 1.24 vs. NVO: 3.84 )
NVO' s 10-Year Yield on cost (5-Year) Range
Min: 3.01   Max: 7.3
Current: 3.84

3.01
7.3
Share Buyback Rate 2.70
NVO's Share Buyback Rate is ranked higher than
97% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -10.10 vs. NVO: 2.70 )
NVO' s 10-Year Share Buyback Rate Range
Min: 3   Max: -0.3
Current: 2.7

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 22.34
NVO's Price/Tangible Book is ranked higher than
64% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 8.73 vs. NVO: 22.34 )
NVO' s 10-Year Price/Tangible Book Range
Min: 1.88   Max: 21.28
Current: 22.34

1.88
21.28
Price/DCF (Projected) 3.88
NVO's Price/DCF (Projected) is ranked higher than
93% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NVO: 3.88 )
NVO' s 10-Year Price/DCF (Projected) Range
Min: 1.3   Max: 22.47
Current: 3.88

1.3
22.47
Price/Median PS Value 1.92
NVO's Price/Median PS Value is ranked higher than
73% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 1.94 vs. NVO: 1.92 )
NVO' s 10-Year Price/Median PS Value Range
Min: 0.16   Max: 1.69
Current: 1.92

0.16
1.69
Price/Peter Lynch Fair Value 1.23
NVO's Price/Peter Lynch Fair Value is ranked higher than
99% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NVO: 1.23 )
NVO' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.07   Max: 1.59
Current: 1.23

0.07
1.59
Price/Graham Number 5.47
NVO's Price/Graham Number is ranked higher than
89% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NVO: 5.47 )
NVO' s 10-Year Price/Graham Number Range
Min: 0.83   Max: 5
Current: 5.47

0.83
5
Earnings Yield (Greenblatt) 4.10
NVO's Earnings Yield (Greenblatt) is ranked higher than
76% of the 475 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. NVO: 4.10 )
NVO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.9   Max: 11
Current: 4.1

3.9
11
Forward Rate of Return (Yacktman) 24.24
NVO's Forward Rate of Return (Yacktman) is ranked higher than
96% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: -10.16 vs. NVO: 24.24 )
NVO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 4.3   Max: 118.6
Current: 24.24

4.3
118.6

Business Description

Industry: Biotechnology » Biotechnology
Compare:AMGN, GILD, BIIB, CELG, CMXHY » details
Traded in other countries:0QIU.UK, NOVO B.Denmark, NONOF.USA, NOVA.Germany, NOVC.Germany
Novo Nordisk is a healthcare company engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The company operates in two business segments, diabetes care and biopharmaceuticals. The diabetes care segment covers insulin's, GLP-1, other protein-related products and projects such as glucagon and protein-related delivery systems, obesity and oral anti-diabetic drugs. The biopharmaceuticals segment covers the therapy areas of hemophilia, growth hormone therapy, hormone replacement therapy and inflammation. The company manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society.
» More Articles for NYSE:NVO

Headlines

Articles On GuruFocus.com
Insider Buys at Halozyme Look to Improve Stock Outlook Sep 18 2014 
Baxter Will Remain Diversified and With Competitive Advantages Sep 02 2014 
Guru Stocks at 52-Week Lows: CHL, TM, SNY, NVO, TSM Sep 02 2014 
Guru Stocks at 52-Week Lows: CHL, TM, SNY, NVO, TSM Aug 23 2014 
GAMCO CIO Howard Ward on Reliable Consumer Stock Ideas Apr 09 2014 
Assessing the New Boss at National Oilwell Varco Mar 31 2014 
Amgen Inc: As Good as It Gets? Feb 20 2014 
Shire PLC: Time to Panic? Feb 07 2014 
Weekly 52-Week Highs Highlight: ACT, NVO, NXPI, WYNN Feb 03 2014 
AstraZeneca: Time to Make a Bet? Steven Cohen Seems to Think It Is Jan 15 2014 

More From Our Partners
Making Money With Charles Payne: 09/26/14 Sep 26 2014 - FOXBUSINESS

More From Other Websites
Today's Stocks Driving Success For The Drugs Industry Sep 29 2014
Novo Nordisk Reveals Fresh Data on Xultophy for Diabetes Sep 22 2014
Five Leading International Stocks Near Buy Points Sep 18 2014
Today's Market Thorns, Roses and All Time Highs... Sep 18 2014
FDA Approves Lilly's Once-Weekly Shot For Diabetes Sep 18 2014
Novo Nordisk Marks 90 Years of Innovating Diabetes Care Sep 18 2014
The Market's Thorns, Roses, and All Time Highs... Sep 17 2014
Novo Nordisk's Tresiba Effective in Children & Adolescents Sep 17 2014
Novo Nordisk's Saxenda Gets Positive Opinion for Obesity Sep 12 2014
Aveva sinks; Novo Nordisk climbs: Europe’s big stock movers Sep 12 2014
[$$] FDA Panel Recommends Approval of Novo Nordisk Obesity Treatment Sep 11 2014
MEDIA ALERT: Denmark's Crown Prince Couple Helps Mark 90 Years of Canadian, Danish Partnership in... Sep 11 2014
Fat Chance? Novo Hopes to Sell its Injectable Diabetes Med as a Diet Drug Sep 10 2014
Investment, Un-American Style Sep 10 2014
3 Stocks Boosting The Drugs Industry Higher Sep 09 2014
Piramal, Exelixis And Novo Nordisk Research Woes Spell Doom For Drug Discovery Scientists Sep 04 2014
Novo Nordisk Drops Anti-Inflammatory R&D Activities Sep 03 2014
[$$] Novo Nordisk's Comeback Needs Nods From Regulators Sep 03 2014
Booming Biotech Market Benefits REIT BioMed Realty Sep 02 2014
Novo Nordisk's Ryzodeg Now in Mexico for Type II Diabetes Sep 02 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK